Invitro activity of tigecycline against Brucella sp. isolated from 1997 to 2009
Abstract number: P1291
Al Johani S., Memish Z.
Background: Brucellosis is an endemic zoonotic infectious disease in Saudi Arabia. To date, there is no optimum antibiotic therapy for brucellosis due to relatively high rates of relapse and treatment failure. The use of new antibiotics, such as tigecycline, may hold future promise.
Objective: The aim of this study was to investigate in vitro activity of tigecycline (TIG) against Brucella spp isolated at Microbiology Laboratory, King AbdulAziz Medical City over the last 12 years.
Material and Methods: A total of 471 Brucella strains, isolated from blood and sterile body fluid and saved at -80 degrees from January 1, 1997 to November 2009, was sub cultured twice then tested against TIG using E-test (AB Biodisk, Sweden ®), and the minimal inhibitory concentration (MIC) was measured, along with MIC50 and MIC90.
Results: A total of 471 Brucella strain sub cultured, out of the 471, there were 8 isolates excluded because it fail to grow. Of the remaining 463 isolates were tested against TIG using E-test, the MIC were determined for each isolates. MIC range (0.0640.125 mg/ml), MIC50 (0.064 mg/ml) and MIC90 (0.094 mg/ml). Out of 464 isolates, there were 286 isolates (61.77%) has an MIC below 0.125 mg/ml, and the rest 176 (38.01%) has an MIC between (0.2501.50 mg/ml).
Of the 287 presumed susceptible strains, there were 136 isolates (47.39%) where their MIC below (0.064 mg/ml) and 151 (52.61%) has MIC between (0.0640.125 mg/ml).
Conclusion: The results of this in vitro study suggest that tigecycline has a promising future to be used as a therapeutic alternative for brucellosis. These observations need to be supported with clinical trials. This is the first study to analyze a large number of brucella isolates at our region.
|Session name:||Abstracts 20th European Congress of Clinical Microbiology and Infectious Diseases|
|Location:||Vienna, Austria, 10 - 13 April 2010|
|Back to top|